Sporamin suppresses growth of xenografted colorectal carcinoma in athymic BALB/c mice by inhibiting liver β-catenin and vascular endothelial growth factor expression

Figure 1 Body weight changes during sporamin treatment.

Figure 2 Establishment of a colorectal cancer in vivo model. Photos taken of intestines from the vehicle group (A) and sporamin-treated group (B). C: Tumor shapes are shown.

Figure 3 Changes in the weight and number of tumors following sporamin administration. ^aP < 0.05 vs vehicle.

Figure 4 Liver histological changes after sporamin treatment. Photomicrographs of hematoxylin and eosin staining of liver sections from the normal control group (A), vehicle group (B), and sporamin group (C). Magnification, 20×.

Figure 5 Immunohistochemical staining for vascular endothelial growth factor and β-catenin in the liver of nude mice after sporamin treatment. Photomicrographs of liver sections from the control group (A), vehicle group (B), and sporamin group (C). Magnification, 40×. VEGF: Vascular endothelial growth factor.

Figure 6 Average optical density of vascular endothelial growth factor and β-catenin in the liver of nude mice after sporamin treatment. Measurements were made using ImageJ; n = 3 per group. ^aP < 0.05 vs vehicle, ^bP < 0.01 vs vehicle. VEGF: Vascular endothelial growth factor.

Figure 7 Concentrations of β-catenin and vascular endothelial growth factor in the liver of nude mice after sporamin treatment. ^bP < 0.01 vs vehicle. VEGF: Vascular endothelial growth factor.

Figure 8 Relative mRNA expression of β-catenin and vascular endothelial growth factor. ^bP < 0.01 vs vehicle.